21 Dec 2015

ABIGO Medical and GU Ventures engages in Cooperation

Abigo Medical AB and GU Ventures just launched a new strategic cooperation based on the common interest in developing new medical devices and pharmaceuticals. The purpose is to promote and achieve a more efficient development of the two areas and thereby, as an effect of the cooperation, be able to do more and better business.

The companies Abigo Medical and GU Ventures pursue development of new medical devices and pharmaceuticals. Abigo manages their own global sales and distribution and is an internationally fast growing and profitable complete life science company in the Västra Götaland region. GU Ventures practice incubator support and seed investments in new research-based businesses related to the University of Gothenburg. The companies have now united in their ambition to develop new innovative projects into commercially attractive businesses. The focus will primarily be on the areas where Abigo has its core, such as infection control, wound care, ear/nose/throat, eyes, and food for special medical purposes.

  • A close dialogue between an incubator such as GU Ventures and a company like Abigo is an important factor in strengthening the building of innovation activities and thereby creating better business contributing to increased benefits for the patient on a global level, says Jan G. Smith, co-founder and Chairman of Abigo Medical. He continues:
  • We are growing rapidly worldwide with good profits and are reinvesting in the future, for example with a large number of new recruitments, the development of our own research and powerful expansion of our own production plant in Askersund. GU Ventures has new activities with new products which we, with our resources, can bring to market.

Abigo and GU Ventures will, within the strategic cooperation, work together with concrete pragmatic activities and measures in order for appropriate innovative projects to more quickly reach a commercially attractive level. The cooperation between Abigo Medical and GU Ventures aims to enhance the results of the respective company’s development of new medical device and pharmaceutical concepts.

  • We see a lot of ideas for new products or processes, which can become commercial successes, continues Klementina Österberg, CEO of GU Ventures. As in all industries, it is necessary they satisfy a specific need and match this to what the industry or healthcare sector wants. Each project will require different kinds of support, they need to be in the right place and get the right set of skills and capital, in order to achieve commercial success. With the support of Abigo many of the ideas can reach this point more quickly and with greater certainty.

The new cooperation between Abigo Medical and GU Ventures has developed over several years, when the companies’ representatives worked together in different configurations. There is a solid trust and a common interest to support and benefit each other, which ensures that the collaboration will provide the important results required.

For more information please contact:
Abigo Medical: Jan G Smith, co-founder and Chairman, +46 31 748 497 32
GU Ventures: Klementina Österberg, CEO, +46 31 786 51 53, +46 70 440 11 90,

Klementina Österbergfor_tryck_2449

Abigo Medical AB
Abigo Medical is a Swedish entrepreneurial pharmaceutical company that owns, develops, manufactures and markets pharmaceuticals and medical devices. Abigo Medical has a wide range of non-prescription and prescription drugs, as well as an assortment of medical products for advanced wound treatment and ear, nose and throat (ENT). In addition, food for special medical purposes is marketed. The company was founded in 1989 by the current owners, brothers Jan G. Smith and Leif Smith, who are both still actively involved in the corporate management. Today Abigo’s products are sold and used in over 60 countries, through its own sales organizations and partners. Abigo’s turnover exceeds 200 million SEK annually with very good profitability, which is reinvested in research and development. For more information, see

GU Ventures
GU Ventures is a Swedish state-owned holding company, whose business has been ranked among the top ten in Europe. Its mission is to start up, fund and with an active incubator support develop new business ideas and companies linked to the University of Gothenburg. The aim is to apply research through commercialization and to translate ideas into viable businesses, thereby creating new jobs and growth as well as to meet several of the major challenges in society. Together with innovators and co-investors, GU Ventures has, over the past 20 years, developed over 120 new ideas which employs over 300 people in about 90 limited liability companies with an annual sales of approximately 300 million SEK annually. GU Ventures sold several of the companies at a profit, and six of the companies are listed on various marketplaces. The portfolio currently consists of 50 holdings with a total value of 1 billion SEK.











25 Sep 2015

ABIGO Medical supports Human Bridge

ABIGO Medical supports the organisation Human Bridge with Sorbact.

A shipment of Sorbact wound care dressings has been sent to Human Bridge to support and help out in countries like Somalia and Irak where a lot of help is now needed.




Human bridge:

Human Bridge is a professional organization specialized in supply of medical equipment. Through contact with Swedish hospitals and biomedical establishments Human Bridge is able to channel substantial  quantities of used but well-functioning equipment to countries around the world.

Our work consists of collecting, repairing and distributing medical supplies and disability equipment mainly to countries in Africa and Eastern Europe. Textiles, such as clothing and footwear, are also collected and goes to direct aid efforts or generate revenue for various aid projects.

The organization’s goal is: To carry out development, relief and social projects on behalf of partners in Sweden and on site in receiving countries.
Read more:



26 Aug 2015

Hydrogel-impregnated dressings for graft fixation: a case series

JOURNAL OF WOUND CARE VOL 24 , NO 7 , JULY 2015,  Choi JS et al


Infection is the second most common cause of graft loss after skin grafting.

This case series describes the use of Sorbact® Gel dressing, a bacteria and fungi-binding hydrogel-impregnated dressing, for the fixation of grafted skin instead of the widely used petrolatum gauze or paraffin gauze. In total seven patients were treated with an age range of 23-86 years old. No infections were seen and the method was effective regardless of wound size, the thickness of the skin harvested and condition of the defect.

Read more

12 Dec 2014

Management of a non-healing postoperative wound using a bacteria and fungi-binding mesh

This case report describes the use of Sorbact®, a bacteria and fungi-binding dressing, to treat a chronic surgical wound in a patient with a history of substance abuse and peripheral arterial disease. The wound had previously been treated unsuccessfully with negative pressure wound therapy and antimicrobial dressings, and had not healed 7 months after surgery. The use of Sorbact was viewed by the treating team as a turning point in wound healing, and its suggested mode of action in enabling wound healing is outlined here.

Paper – Hege – Management of a non-healing postoperative wound using a bacteria and fungi binding mesh

or use below link straight to the pdf:

Paper - Hege - Management of a non-healing postoperative wound using a bacteria and fungi binding mesh_Sida_1.

24 Oct 2014

New Publication – Adhesion of meticillin-resistant Staphylococcus aureus to DACC-coated dressings








SUMMARY OF IN VITRO BINDING PUBLICATION  – link to the whole article above.

A.C. Ronner, J. Curtin, N. Karami, and U. Ronner.  Adhesion of meticillin-resistant Staphylococcus aureus to DACC-coated dressings.

The above study was performed at Sahlgrenska Science Park, Gothenburg University in Sweden and was aimed to demonstrate comparable binding of clinical Staphylococcus aureus strains relative to multiple MRSA strains using a DACC-coated dressing as an adhesion material.   Eleven isolates were used in this study. The MRSA strains were isolated from different inpatient and outpatient wounds. All the MRSA isolates in the study were clinical in origin and caused infection in the patients seeking treatment.

To study the binding of bacteria to the dressing sur­face, an inoculum of each strain was added to the wound dressing. After an opportunity for bacteria binding was afforded, each sample dressing was rinsed multiple times to ensure the release of loosely adhered cells. The number of bacteria adhering to the dressing were then determined by a standardized luminescence technique for ATP detection.Eleven strains of Staphylococcus aureus were examined including 9 x MRSA, all of which efficiently and equally adhered to the DACC-coated dressing. The binding capacity was in the same range 0.7–2.9×106 CFU/cm2 regardless of the antibiotic resistance properties of the specific strain.  A comparison of the adhesion capacity between a DACC-coated dressing material and an uncoated con­trol with the Staphylococcus aureus control strain was performed. The DACC-coated material bound a mean value of 1.5×106 CFU/cm2, whereas uncoated binding was reduced to a mean value of 6.8×104 CFU/cm2, which was significantly lower (p<0.0001).

The decrease of wound bioburden of Staphylococcus aureus including MRSA is the result of the high binding capacity shown in this study and by earlier data. The findings in this study strengthen the held view that development of antibiotic resistance has minimal impact on the surface structures of the microorganisms in wounds.

Further clinical work is intended to follow this study with the intention to demonstrate early involvement of Sorbact® in the management of wounds (in both open wound management and surgical site infection prevention) will enhance wound outcomes and relieve the burden placed upon antibiotics.


15 Sep 2014

New Publication – Adhesion of the ulcerative pathogen Mycobacterium ulcerans to DACC-coated dressings.

ABIGO Medical are very proud to report the recent publication from the Pasteur Institute in Paris regarding the binding capabilities of Sorbact. The study is titled:

Geroult S, Phillips RO, Demangel C. Adhesion of the ulcerative pathogen Mycobacterium ulcerans to DACC-coated dressings. J Wound Care. 2014 Aug;23(8):417-24.

The bacteria Mycobacterium ulcerans is responsible for the formation of the Buruli ulcer, a disease process that results in a high morbidity and economic impost across sub-Saharan Africa and many third world countries.  This study supports the well documented bacteria binding capability of the Sorbact technology, furthermore, the study will lead into future clinical trials aimed at assisting management of patients suffering from Buruli ulcer disease.

The focus of ABIGO Medical is to help alleviate the heavy burden placed on antibiotics through both infection prevention measures and in the assisted management of wounds like the Buruli ulcer.  We are very optimistic these findings will promote further high quality clinical research into this and similar areas of medicine.

26 May 2014

ABIGO Medical AB – celebrating its 25th anniversary, 25 years of success!

This was recognized this year on May 9 to 10 with both a party as a two-day internal arrangement where all the company’s employees participated. Also deliberate plans and strategies for the company’s future expansion was presented.

”Research and development, innovative & unique products, globalization, growth and sustainability” are the key words for the company.

20140509 ABIGO 25 år
ABIGO is a complete pharmaceutical company with integrated R&D, manufacturing and marketing. The headquarters are located in Gothenburg, where we also have our dedicated research laboratory. We have our own manufacturing facility in Askersund. ABIGO has over 85 employees and an annual revenue of approximately SEK 200 million.

ABIGO is focused internationally with an extensive international distribution network. In Sweden, Norway and Denmark, ABIGO manages its own sales organization while through a global network of distributors our products are sold in over 70 countries worldwide. The international growth of ABIGO has taken place at a significant rate and a rate that will continue to improve.

ABIGO operates two business areas; pharmaceuticals, and medical devices. The pharmaceutical division comprises a broad range of both prescription – and OTC products while the medical devices division consists of an advanced wound care product line and ENT (ear-nose-throat) products.

ABIGO is a family owned Swedish pharmaceutical company, founded 1989 by the two Brothers Jan G. Smith and Leif Smith and still managed and wholly owned by them. The company has the highest credit rating, AAA. This means good economy, quick decisions but also a positive tone. It should be stimulating to work with ABIGO, good spirit in the company is a key word for us.



12 May 2014

AWMA 2014 – Best Poster Award

Congratulations to Carin Ottosson and Ann-Mari Fagerdahl for winning the ‘Best Poster Award’ at the Australian Wound Management Association (AWMA) conference that was recently held on the Gold Coast, Australia.  The poster was titled “Bacteria and fungi binding mesh used as a NPWT wound filler for managing Pseudomonas aeruginosa”.

Their prize was received in front of 900 applauding AWMA delegates.


20 Feb 2014

Otovent in an updated packaging


Otovent is now released in its new package! We are happy to be able to introduce this package on all markets in the world.

For more information also see 





03 Jun 2013

NPWT Wound Filler

At EWMA in Copenhagen, ABIGO launched Sorbact® NPWT Wound Filler. Product development truly driven by the market.
When a lot of cases was coming in from all corners of the world where Sorbact® was being used as a wound filler in NPWT treatment, ABIGO realized that we needed to make a product available.

Cooperating with some of the world leading experts in the field of NPWT, ABIGO this year at EWMA released Sorbact® NPWT Wound Filler for the European market.

The main advantages against foam fillers is that Sorbact® has limited tissue ingrowth for easy and painless removal. In addition it is easy to line and adapt to complex wound cavities. The main advantage compared to gauze is the great liquid handling capacity of Sorbact®.

Please download the Sorbact® NPWT folder to learn more. You’ll find it under products.


Ref no: 98425

17 x 28 cm (7 x 11 in)

Ref no: 98410

10 x 100 cm (4 x 39 in)